indazoles has been researched along with carboplatin in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 1 (4.55) | 29.6817 |
| 2010's | 16 (72.73) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Epelbaum, R; Frei, E; Herman, TS; Holden, SA; Liu, SD; Teicher, BA | 1 |
| Bottalico, C; Brandi, M; Catino, A; De Lena, M; De Mitrio, A; Gargano, G; Guida, M; Latorre, A; Leone, B; Lorusso, V; Vallejo, C | 1 |
| Kaye, SB | 1 |
| Curtis, LB; du Bois, A; Harter, P; Mitrica, I; Ray-Coquard, I; Vergote, I; Wimberger, P | 1 |
| Ball, HA; Burris, HA; Dar, MM; Dowlati, A; Gainer, SD; Infante, JR; Jones, SF; Levinson, KT; Lindquist, D; Moss, RA; Spigel, DR; Suttle, AB; Tan, AR | 1 |
| Arriola, E; Cohen, RB; De Castro Carpeño, J; Herbst, RS; Kim, S; Kozloff, MF; Krzakowski, M; Martin, LP; Olszanski, AJ; Rado, TA; Rosbrook, B; Samuel, TA; Tarazi, J; Tortorici, M | 1 |
| Bycott, P; Chen, C; Chmielowska, E; de Besi, P; Havel, L; Ingrosso, A; Kim, S; Olszanski, AJ; Popat, S; Sawrycki, P; Schiller, JH; Swieboda-Sadlej, A; Twelves, C; Williams, JA | 1 |
| Dayer, LE; Hutchins, LF; Johnson, JT | 1 |
| Carlson, DM; Horai, T; Horiike, A; Horinouchi, H; Kaneda, H; McKee, MD; Nakagawa, K; Nishio, M; Nokihara, H; Ohyanagi, F; Okabe, T; Tamura, T; Terashima, M; Xiong, H; Yamamoto, N | 1 |
| Axelrod, R; Barrios, CH; Belani, CP; Carlson, DM; Devanarayan, V; Gorbunova, VA; Kolman, P; Makhson, A; McKee, MD; McKeegan, EM; Owonikoko, TK; Pereira, JR; Pittman, KB; Qian, J; Qin, Q; Ramalingam, SS; Ricker, JL; Segalla, JG; Shtivelband, M; Soo, RA; Srkalovic, G | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Algazi, AP; Bastian, BC; Behr, S; Cha, E; Chong, K; Coakley, F; Cortez, B; Daud, AI; Hwang, J; Liu, S; McCalmont, T; Ortiz-Urda, SM; Pampaloni, MH; Quiroz, A | 1 |
| Bokemeyer, C; Oechsle, K; Oing, C; Rink, M; Seidel, C; von Amsberg, G | 1 |
| Ansell, PJ; Bhathena, A; Carlson, DM; Chakravartty, A; Chan, S; Chandran, RK; Davis, G; Devanarayan, V; Dowell, BL; Gawel, SH; McKee, MD; McKeegan, EM; Ramalingam, SS; Ricker, JL | 1 |
| Fujiwara, Y; Horiike, A; Inatani, M; Iwasa, S; Kitazono, S; Kondo, S; Nishio, M; Tamura, K; Tanabe, Y; Tanaka, J; Yamamoto, N; Yanagitani, N | 1 |
| Kaneko, T; Koike, K; Kurata, T; Motobayashi, M; Nakazawa, Y; Sano, K; Shigemura, T; Sumi, T; Suzuki, S; Watanabe, T | 1 |
| Agelaki, S; Fountzilas, G; Georgoulias, V; Hartabilas, E; Karavassilis, V; Katsaounis, P; Kentepozidis, N; Koinis, F; Kotsakis, A; Messaritakis, I; Peroukidis, S; Samantas, E; Varthalitis, II | 1 |
| Adjei, AA; Bahleda, R; Besse, B; Dy, GK; Ferte, C; Groen, HJM; Lin, W; Morrissey, K; Planchard, D; Schutzman, JL; Shankar, G; Soria, JC; Ware, J; Zhou, J | 1 |
| Han, X; Lu, C; Lv, S; Qiao, P; Ren, C; Sun, Y; Wang, D; Wang, L; Yang, T; Yu, Z | 1 |
| Ebata, T; Fujiwara, K; Fujiwara, Y; Hasegawa, K; Kato, T; Nishikawa, T; Noguchi, E; Shimomura, A; Sudo, K; Tamura, K; Yonemori, K | 1 |
| Alexandre, J; Kalbacher, E; Leary, A; Prulhière, K; Ray-Coquard, I; Selle, F | 1 |
| Bessudo, A; Dezube, BJ; Duncan, M; Evilevitch, L; Gabrail, N; Guo, W; Hamilton, E; Kumar, S; Lu, S; Patel, MR; Rodon, J; Sachdev, J; Yap, TA | 1 |
3 review(s) available for indazoles and carboplatin
| Article | Year |
|---|---|
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Factors; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Pyrimidines; Salvage Therapy; Sulfonamides; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Maintenance Chemotherapy; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2021 |
12 trial(s) available for indazoles and carboplatin
| Article | Year |
|---|---|
Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Drug Synergism; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms | 1997 |
Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Early Termination of Clinical Trials; Feasibility Studies; Female; Genital Neoplasms, Female; Humans; Indazoles; Middle Aged; Paclitaxel; Pyrimidines; Sulfonamides | 2012 |
Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Pyrimidines; Sulfonamides; Treatment Outcome | 2012 |
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Imidazoles; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Treatment Outcome | 2012 |
Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Proportional Hazards Models; Treatment Outcome | 2014 |
A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Chemotherapy-Induced Febrile Neutropenia; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Japan; Leukopenia; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Severity of Illness Index; Thrombocytopenia; Tumor Burden | 2014 |
Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Phenylurea Compounds; Receptors, Platelet-Derived Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carboplatin; Dideoxynucleosides; Female; Humans; Imidazoles; Indazoles; Male; Melanoma; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Radiography; Treatment Outcome | 2015 |
Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Carboplatin; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Sulfonamides; Treatment Outcome | 2017 |
Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carboplatin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Pyrimidines; Small Cell Lung Carcinoma; Sulfonamides; Treatment Outcome | 2017 |
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-s
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Sulfonamides; Treatment Outcome | 2017 |
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Humans; Indazoles; Neoplasms; Paclitaxel; Piperidines; Vascular Endothelial Growth Factor A | 2022 |
7 other study(ies) available for indazoles and carboplatin
| Article | Year |
|---|---|
Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carboplatin; Carmustine; Drug Resistance; Drug Screening Assays, Antitumor; Drug Synergism; Fibrosarcoma; Humans; Indazoles; Mammary Neoplasms, Animal; Mice; Organoplatinum Compounds; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1991 |
New drugs for ovarian cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Bevacizumab; BRCA2 Protein; Carboplatin; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Ovarian Neoplasms; Paclitaxel; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides; Ubiquitin-Protein Ligases; Vascular Endothelial Growth Factor A | 2008 |
Treatment of metastatic melanoma with pazopanib: A report of five patient cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Indazoles; Male; Melanoma; Middle Aged; Pyrimidines; Sulfonamides | 2015 |
Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Indazoles; Keratin-19; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Phenylurea Compounds | 2015 |
Dramatic Reduction in Tumor Size During 5 Months of Pazopanib Therapy in Combination With Ifosfamide, Carboplatin, and Etoposide in an Early Infant With Progressive Soft Tissue Sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; Indazoles; Infant; Male; Pyrimidines; Remission Induction; Sarcoma; Sulfonamides | 2017 |
Phosphorylation of HSF1 by PIM2 Induces PD-L1 Expression and Promotes Tumor Growth in Breast Cancer.
Topics: Aminopyridines; Animals; Autophagy; B7-H1 Antigen; Benzylidene Compounds; Breast Neoplasms; Carboplatin; F-Box-WD Repeat-Containing Protein 7; Female; Gene Expression Regulation, Neoplastic; Heat Shock Transcription Factors; Humans; Indazoles; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplasm Proteins; Phosphorylation; Protein Binding; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Stability; Proto-Oncogene Proteins; RNA Interference; RNA, Small Interfering; Substrate Specificity; Thiazolidinediones; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2019 |
Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Docetaxel; Doxorubicin; Female; Humans; Ifosfamide; Indazoles; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome; Uterine Neoplasms | 2020 |